Institute of Radioisotopes-Radiodiagnostic Products, National Center for Scientific Research, Athens, Greece.
Bioconjug Chem. 2009 May 20;20(5):856-67. doi: 10.1021/bc800475k.
It has been shown that gastrin releasing peptide receptors (GRPRs) are overexpressed in various types of cancer cells. Bombesin is an analogue of the mammalian GRP that binds with high specificity and affinity to GRPRs. Significant research efforts have been lately devoted to the design of radiolabeled 8 or 14 aminoacid bombesin (BN) peptides for the detection (either with gamma or positron emitting radionuclides) and therapy (with beta(-) emitting radionuclides) of cancer. The specific aim of the present study was to further investigate the radiolabeled peptide structure and to determine whether the total absence of a linker or the use of a basic diverse amino acid linker could influence the biodistribution profile of the new compounds for specific targeting of human prostate cancer. Thus, two new derivatives with the structure Gly-Gly-Cys-X-BN[2-14], where linker X is either zero (I) or Orn-Orn-Orn (Orn: ornithine) (II) were designed and synthesized. The corresponding (99m)Tc-BN derivatives were obtained with high radiochemical yield (>98%) and had almost identical retention times in RP-HPLC with the (185/187)Re complexes, which were also characterized by ESI-MS. Metabolic stability was found to be high in human plasma, moderate in PC-3 cells, and rather low in mouse liver and kidney homogenates for both BN derivatives studied. The BN derivative without the spacer was less stable in cell culture and liver homogenates. A satisfactory binding affinity to GRPRs, in the nanomolar range, was obtained for both BN derivatives as well as for their Re complexes, with BN (II) demonstrating the highest one. In vitro internalization/externalization assays indicated that approximately 6% of BN (I) and approximately 25% of BN (II) were internalized into PC-3 cells. In vivo evaluation in normal Swiss mice and in tumor bearing SCID mice showed that BN (II) presented higher tumor and pancreas uptake than BN (I). Small animal SPECT dynamic imaging, carried out after an injection of BN (II) in mice bearing PC-3 tumors, resulted in PC-3 tumor delineation with low background activity. Overall, this study performed for two new N(3)S-X-BN[2-14] derivatives indicated that hydrophilicity and charge strongly affected the in vitro and in vivo binding properties and the biodistribution pattern. This finding is confirmed by SPECT imaging of BN (II), which is under further in vivo evaluation for detecting cancer-positive GRPRs.
已经表明,胃泌素释放肽受体(GRPRs)在各种类型的癌细胞中过度表达。蛙皮素是哺乳动物 GRP 的类似物,与 GRPRs 具有高特异性和亲和力结合。最近,人们投入了大量的研究努力来设计放射性标记的 8 或 14 个氨基酸的蛙皮素(BN)肽,用于癌症的检测(用伽马或正电子发射放射性核素)和治疗(用β(-)发射放射性核素)。本研究的具体目的是进一步研究放射性标记肽的结构,并确定是否完全没有接头或使用碱性不同的氨基酸接头会影响新化合物的生物分布谱,以实现人前列腺癌的特异性靶向。因此,设计并合成了两种具有结构 Gly-Gly-Cys-X-BN[2-14]的新衍生物,其中接头 X 要么为零(I),要么为 Orn-Orn-Orn(Orn:鸟氨酸)(II)。用高放射性化学产率(>98%)获得了相应的(99m)Tc-BN 衍生物,并且在 RP-HPLC 中与(185/187)Re 络合物的保留时间几乎相同,这些络合物也通过 ESI-MS 进行了表征。在人血浆中发现 BN 衍生物的代谢稳定性较高,在 PC-3 细胞中中等,在小鼠肝和肾匀浆中较低。在细胞培养和肝匀浆中,没有间隔物的 BN 衍生物的稳定性较低。两种 BN 衍生物及其 Re 络合物均获得了对 GRPRs 的满意的结合亲和力,在纳摩尔范围内,BN(II)表现出最高的亲和力。体外内化/外排试验表明,约 6%的 BN(I)和约 25%的 BN(II)被内化到 PC-3 细胞中。在正常瑞士小鼠和荷瘤 SCID 小鼠中的体内评价表明,BN(II)在胰腺中的摄取高于 BN(I)。在荷有 PC-3 肿瘤的小鼠中注射 BN(II)后进行小动物 SPECT 动态成像,结果导致 PC-3 肿瘤的描绘,背景活性低。总体而言,这项针对两种新的 N(3)S-X-BN[2-14]衍生物的研究表明,亲水性和电荷强烈影响体外和体内结合特性以及生物分布模式。这一发现通过 BN(II)的 SPECT 成像得到证实,BN(II)正在进一步进行体内评估,以检测癌症阳性的 GRPRs。